In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

Looking to refresh your skin care arsenal? Right now, there are a number of La Roche-Posay products for 20% on Amazon — ...

Roche’s subcutaneous version of its multiple sclerosis (MS) med Ocrevus triumphed in a key late-stage study, likely setting up a new opportunity for the blockbuster drug. The study, called OCARINA II, ...

La Roche-Posay is a New York-based brand, but their roots are in France. The brand was founded in a French town of the same name in 1975, and it still manufactures products there today. To understand ...

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the rumour ...

Roche has removed eight phase 1 and 2 oncology and neurology candidates from its pipeline as part of a set of “trade-offs” intended to “increase the overall portfolio value and speed up development.” ...

Swiss pharmaceuticals company Roche agreed to acquire U.S.-based weight-loss drugmaker Carmot Therapeutics, which develops anti-obesity and diabetes drugs, for $2.7 billion, according to a press ...

S witzerland-based biotechnology giant Roche plans to invest $50 billion in the United States in the next five years. These investments will further strengthen Roche’s U.S. footprint with 13 ...

Even as Roche executives on Thursday espoused confidence in the company’s resilience and growth potential over the next several years, a mix of exchange rate fluctuations and lackluster pharmaceutical ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the drug in preclinical-stage patients at elevated risk of cognitive decline. The ...

Swiss pharmaceutical giant Roche agreed Thursday to pay $46.8 billlion in cash to buy the 44 percent of California-based biotech pioneer Genentech that it doesn't already own, ending a long corporate ...